{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:54:04Z","timestamp":1769820844902,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00292-023-01198-1","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T08:02:18Z","timestamp":1682668938000},"page":"197-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Histologische und molekularpathologische Besonderheiten von Tumoren des peripheren Nervensystems","Histological and molecular characteristics of tumours of the peripheral nervous system"],"prefix":"10.1007","volume":"44","author":[{"given":"Patrick N.","family":"Harter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Ronellenfitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"1198_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/NATURE26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper\u00a0D, Jones\u00a0DTW, Sill\u00a0M et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469\u2013474. https:\/\/doi.org\/10.1038\/NATURE26000","journal-title":"Nature"},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00401-016-1540-6","volume":"3","author":"M R\u00f6hrich","year":"2016","unstructured":"R\u00f6hrich\u00a0M, Koelsche\u00a0C, Schrimpf\u00a0D et al (2016) Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol 3:877\u2013887. https:\/\/doi.org\/10.1007\/s00401-016-1540-6","journal-title":"Acta Neuropathol"},{"key":"1198_CR3","unstructured":"WHO Classification of Tumours Editorial Board (2021) Central nervous system tumours. Lyon (France): International Agency for Research on Cancer. https:\/\/tumourclassification.iarc.who.int\/chapters\/45. Zugegriffen: 1. Aug. 2022"},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/modpathol.2014.109","volume":"28","author":"M Pekmezci","year":"2015","unstructured":"Pekmezci\u00a0M, Reuss\u00a0DE, Hirbe\u00a0AC et\u00a0al (2015) Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol 28:187\u2013200. https:\/\/doi.org\/10.1038\/modpathol.2014.109","journal-title":"Mod Pathol"},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/00000478-198112000-00001","volume":"5","author":"JM Woodruff","year":"1981","unstructured":"Woodruff\u00a0JM, Susin\u00a0M, Godwin\u00a0TA (1981) Cellular schwannoma: a\u00a0variety of schwannoma sometimes mistaken for a\u00a0malignant tumor. Am J Surg Pathol 5:733\u2013744. https:\/\/doi.org\/10.1097\/00000478-198112000-00001","journal-title":"Am J Surg Pathol"},{"key":"1198_CR6","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/GCC.22254","volume":"54","author":"L Wang","year":"2015","unstructured":"Wang\u00a0L, Zehir\u00a0A, Sadowska\u00a0J et al (2015) Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP-array and next generation sequencing analysis. Genes Chromosomes Cancer 54:463\u2013471. https:\/\/doi.org\/10.1002\/GCC.22254","journal-title":"Genes Chromosomes Cancer"},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/NEN.0000000000000238","volume":"74","author":"J\u2011E Oh","year":"2015","unstructured":"Oh\u00a0J\u2011E, Ohta\u00a0T, Satomi\u00a0K et al (2015) Alterations in the NF2\/LATS1\/LATS2\/YAP pathway in schwannomas. J Neuropathol Exp Neurol 74:952\u2013959","journal-title":"J Neuropathol Exp Neurol"},{"key":"1198_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3688","author":"S Agnihotri","year":"2016","unstructured":"Agnihotri\u00a0S, Jalali\u00a0S, Wilson\u00a0MR et\u00a0al (2016) The genomic landscape of schwannoma. Nat Genet. https:\/\/doi.org\/10.1038\/ng.3688","journal-title":"Nat Genet"},{"key":"1198_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1634\/theoncologist.2012-0162","volume":"17","author":"VL Merker","year":"2012","unstructured":"Merker VL, Esparza S, Smith MJ et al (2012) Clinical features of Schwannomatosis: a retrospective analysis of 87 patients; clinical features of Schwannomatosis: a retrospective analysis of 87 patients. Oncologist 17:1317\u20131322. https:\/\/doi.org\/10.1634\/theoncologist.2012-0162","journal-title":"Oncologist"},{"key":"1198_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00439-016-1753-8","volume":"136","author":"H Kehrer-Sawatzki","year":"2017","unstructured":"Kehrer-Sawatzki\u00a0H, Farschtschi\u00a0S, Mautner\u00a0V\u2011F, Cooper\u00a0DN (2017) The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis. Hum Genet 136:129\u2013148. https:\/\/doi.org\/10.1007\/s00439-016-1753-8","journal-title":"Hum Genet"},{"key":"1198_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/PAP.0000000000000197","volume":"25","author":"JF Longo","year":"2018","unstructured":"Longo\u00a0JF, Weber\u00a0SM, Turner-Ivey\u00a0BP, Carroll\u00a0SL (2018) Recent advances in the diagnosis and pathogenesis of Neurofibromatosis type 1 (NF1)-associated peripheral nervous system neoplasms. Adv Anat Pathol 25:353\u2013368. https:\/\/doi.org\/10.1097\/PAP.0000000000000197","journal-title":"Adv Anat Pathol"},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/GCC.20921","volume":"50","author":"E Beert","year":"2011","unstructured":"Beert\u00a0E, Brems\u00a0H, Dani\u00ebls\u00a0B et\u00a0al (2011) Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer 50:1021\u20131032. https:\/\/doi.org\/10.1002\/GCC.20921","journal-title":"Genes Chromosomes Cancer"},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/neuonc\/noz028","volume":"21","author":"A Pemov","year":"2019","unstructured":"Pemov\u00a0A, Hansen\u00a0NF, Sindiri\u00a0S et al (2019) Low mutation burden and frequent loss of CDKN2A\/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1\u2011associated atypical neurofibromas. Neuro Oncol 21:981\u2013992. https:\/\/doi.org\/10.1093\/neuonc\/noz028","journal-title":"Neuro Oncol"},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ANA.24854","volume":"81","author":"CJ Klein","year":"2017","unstructured":"Klein\u00a0CJ, Wu\u00a0Y, Jentoft\u00a0ME et\u00a0al (2017) Genomic analysis reveals frequent TRAF7 mutations in intraneural perineuriomas. Ann Neurol 81:316\u2013321. https:\/\/doi.org\/10.1002\/ANA.24854","journal-title":"Ann Neurol"},{"key":"1198_CR15","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1097\/PAS.0B013E3181ACCC6C","volume":"33","author":"JL Hornick","year":"2009","unstructured":"Hornick\u00a0JL, Bundock\u00a0EA, Fletcher\u00a0CDM (2009) Hybrid schwannoma\/perineurioma: clinicopathologic analysis of 42 distinctive benign nerve sheath tumors. Am J Surg Pathol 33:1554\u20131561. https:\/\/doi.org\/10.1097\/PAS.0B013E3181ACCC6C","journal-title":"Am J Surg Pathol"},{"key":"1198_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/PAS.0B013E31824D3155","volume":"36","author":"A Harder","year":"2012","unstructured":"Harder\u00a0A, Wesemann\u00a0M, Hagel\u00a0C et\u00a0al (2012) Hybrid neurofibroma\/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am J Surg Pathol 36:702\u2013709. https:\/\/doi.org\/10.1097\/PAS.0B013E31824D3155","journal-title":"Am J Surg Pathol"},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1172\/JCI130787","volume":"130","author":"MW Ronellenfitsch","year":"2020","unstructured":"Ronellenfitsch\u00a0MW, Harter\u00a0PN, Kirchner\u00a0M et\u00a0al (2020) Targetable ERBB2 mutations identified in neurofibroma\/schwannoma hybrid nerve sheath tumors. J\u00a0Clin Invest 130:2488\u20132495. https:\/\/doi.org\/10.1172\/JCI130787","journal-title":"J Clin Invest"},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","volume":"39","author":"DGR Evans","year":"2002","unstructured":"Evans DGR, Baser ME, Mcgaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311\u2013314. https:\/\/doi.org\/10.1136\/jmg.39.5.311","journal-title":"J Med Genet"},{"key":"1198_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/modpathol.2015.134","volume":"29","author":"I-M Schaefer","year":"2016","unstructured":"Schaefer\u00a0IM, Fletcher\u00a0CD, Hornick\u00a0JL (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4\u201313. https:\/\/doi.org\/10.1038\/modpathol.2015.134","journal-title":"Mod Pathol"},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/PAS.0000000000001242","volume":"43","author":"IM Schaefer","year":"2019","unstructured":"Schaefer\u00a0IM, Dong\u00a0F, Garcia\u00a0EP et\u00a0al (2019) Recurrent SMARCB1 inactivation in epithelioid malignant peripheral nerve sheath tumors. Am J Surg Pathol 43:835\u2013843. https:\/\/doi.org\/10.1097\/PAS.0000000000001242","journal-title":"Am J Surg Pathol"},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/S40478-019-0792-5","volume":"7","author":"FJ Rodriguez","year":"2019","unstructured":"Rodriguez\u00a0FJ, Graham\u00a0MK, Brosnan-Cashman\u00a0JA et al (2019) Telomere alterations in neurofibromatosis type 1\u2011associated solid tumors. Acta Neuropathol Commun 7:139. https:\/\/doi.org\/10.1186\/S40478-019-0792-5","journal-title":"Acta Neuropathol Commun"},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/BPA.12228","volume":"25","author":"C Koelsche","year":"2015","unstructured":"Koelsche\u00a0C, Hovestadt\u00a0V, Jones\u00a0DTW et\u00a0al (2015) Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles. Brain Pathol 25:202\u2013208. https:\/\/doi.org\/10.1111\/BPA.12228","journal-title":"Brain Pathol"},{"key":"1198_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/S00401-009-0611-3","volume":"119","author":"HVN K\u00fcsters-Vandevelde","year":"2010","unstructured":"K\u00fcsters-Vandevelde\u00a0HVN, Klaasen\u00a0A, K\u00fcsters\u00a0B et al (2010) Activating mutations of the GNAQ gene: a\u00a0frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 119:317\u2013323. https:\/\/doi.org\/10.1007\/S00401-009-0611-3","journal-title":"Acta Neuropathol"},{"key":"1198_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/S11060-015-2052-2","volume":"127","author":"J van de Nes","year":"2016","unstructured":"van de Nes\u00a0J, Gessi\u00a0M, Sucker\u00a0A et\u00a0al (2016) Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. J\u00a0Neurooncol 127:435\u2013444. https:\/\/doi.org\/10.1007\/S11060-015-2052-2","journal-title":"J Neurooncol"},{"key":"1198_CR25","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1038\/modpathol.2017.91","volume":"30","author":"S Le Guellec","year":"2017","unstructured":"Le Guellec\u00a0S, Macagno\u00a0N, Velasco\u00a0V et\u00a0al (2017) Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: A study of 387\u00a0cases including mimicking lesions. Mod Pathol 30:1677\u20131687. https:\/\/doi.org\/10.1038\/modpathol.2017.91","journal-title":"Mod Pathol"},{"key":"1198_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/IJC.30828","volume":"141","author":"P Horak","year":"2017","unstructured":"Horak\u00a0P, Klink\u00a0B, Heining\u00a0C et\u00a0al (2017) Precision oncology based on omics data: The NCT Heidelberg experience. Int J Cancer 141:877\u2013886. https:\/\/doi.org\/10.1002\/IJC.30828","journal-title":"Int J Cancer"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01198-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-023-01198-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01198-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T17:04:34Z","timestamp":1683219874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-023-01198-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s00292-023-01198-1","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"12 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>P.N.\u00a0Harter<\/b>: A.\u00a0Finanzielle Interessen: P.\u00a0Harter gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Professor f\u00fcr molekulare Neuropathologie, LMU M\u00fcnchen | Mitgliedschaft: DGNN. <b>K.J.\u00a0Weber<\/b>: A.\u00a0Finanzielle Interessen: K.J.\u00a0Weber gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Neuropathologin im Neurologischen Institut (Edinger-Institut) der Universit\u00e4tsklinik Frankfurt | Mitgliedschaft: Deutsche Gesellschaft f\u00fcr Neuropathologie und Neuroanatomie (DGNN). <b>M.W.\u00a0Ronellenfitsch<\/b>: A.\u00a0Finanzielle Interessen: M.\u00a0Ronellenfitsch gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Oberarzt, Dr. Senckenbergisches Institut f\u00fcr Neuroonkologie, Universit\u00e4tsklinikum Frankfurt, Goethe Universit\u00e4t | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie, Neuroonkologische Arbeitsgemeinschaft (NOA) der Deutschen Krebsgesellschaft (DKG).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}